ABSTRACT
BACKGROUND: A pharmacodynamic comparison between ticagrelor and prasugrel after fibrinolytic therapy has not yet been performed. METHODS: In the single-center SAMPA trial, 50 consecutive STEMI patients previously treated with clopidogrel and undergoing a pharmacoinvasive strategy were randomized to either a ticagrelor (n=25) 180mg loading dose followed by 90mg bid, or a prasugrel (n=25) 60mg loading dose followed by 10mg/day, initiated after fibrinolytic therapy but before angiography. Platelet reactivity was assessed with the VerifyNow P2Y12 assay at 0, 2, 6, and 24h after randomization. RESULTS: Mean times from fibrinolysis to prasugrel or ticagrelor administration were 11.1±6.9 and 13.3±6.3h, respectively (p=0.24). The values of PRU decreased significantly from baseline to 2h (all p<0.001) and from 2h to 6h (all p<0.001) in both groups. There was no difference in PRU values between 6h and 24h. The mean PRU values at 0, 2, 6, and 24h were 234.9, 127.8, 45.4, and 48.0 in the prasugrel group and 233.1, 135.1, 67.7, and 56.9 in the ticagrelor group, respectively. PRU values did not significantly differ between groups at any time period of the study. CONCLUSIONS: In patients with STEMI treated with fibrinolytic therapy, platelet inhibition after clopidogrel is suboptimal and can be further increased with more potent agents. Ticagrelor and prasugrel demonstrated a similar extent of P2Y12 receptor inhibition within 24h, although maximal platelet inhibition after these potent agents was not achieved for 6h.
Subject(s)
Adenosine/analogs & derivatives , Prasugrel Hydrochloride/administration & dosage , ST Elevation Myocardial Infarction/drug therapy , Thrombolytic Therapy/methods , Adenosine/administration & dosage , Coronary Angiography , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Male , Middle Aged , Platelet Aggregation Inhibitors/administration & dosage , Prospective Studies , Purinergic P2Y Receptor Antagonists/administration & dosage , ST Elevation Myocardial Infarction/diagnosis , Ticagrelor , Time Factors , Treatment OutcomeABSTRACT
A regurgitação mitral (RM) é a doença valvar mais prevalente nos Estados Unidos e sua prevalência aumenta a cada ano devido ao envelhecimento populacional. Independentemente da etiologia, a RM sintomática grave cursa com prognóstico desfavorável. O procedimento cirúrgico ainda é o tratamento padrão para essa patologia; porém, como vários pacientes não são submetidos à cirurgia devido ao alto risco, o tratamento percutâneo com MitraClip surgiu como opção viável. A segurança, eficácia e durabilidade do reparo valvar percutâneo com MitraClip já foram demonstradas em estudos randomizados e, com isso, sua indicação vem-se expandindo
Mitral regurgitation (MR) is the most prevalent valve disease in the United States and its prevalence is increasing every year due to population aging. Regardless of the etiology, severe symptomatic MR presents with an unfavorable prognosis. The surgical procedure is still the standard treatment for this pathology, however, various patients do not receive this treatment because of a high surgical risk, and percutaneous treatment with MitraClip has emerged as a viable option. The safety, efficacy, and durability of percutaneous valve repair with the MitraClip have already been demonstrated in randomized trials, and as a result, its indication has been expanding
